{
    "2019-10-01": [
        [
            {
                "time": "",
                "original_text": "复锐医疗科技(01696-HK)拟议股权变动",
                "features": {
                    "keywords": [
                        "复锐医疗科技",
                        "股权变动",
                        "01696-HK"
                    ],
                    "sentiment_score": 0.5,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医疗"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "",
                "original_text": "复星医药子公司拟3.9亿港元受让复锐医疗科技股权",
                "features": {
                    "keywords": [
                        "复星医药",
                        "子公司",
                        "3.9亿港元",
                        "复锐医疗科技",
                        "股权受让"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医疗"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "",
                "original_text": "专访复星医药董事长、复宏汉霖主席兼非执行董事陈启宇：单抗龙头复宏汉霖赴港上市 多款产品陆续进入商业化阶段",
                "features": {
                    "keywords": [
                        "复星医药",
                        "陈启宇",
                        "复宏汉霖",
                        "赴港上市",
                        "单抗龙头",
                        "商业化阶段"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医疗",
                        "生物科技"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            }
        ]
    ]
}